Improved Viral Suppression After Treatment Optimization in HIV-Infected Patients With Persistent Low-Level Viremia

Michael J. McConnell, Julian Mier-Mota, Fernando Flor-Parra, Francisco J. Martinez-Fernandez, Luis F. Lopez-Cortes, Pompeyo Viciana, Felipe Fernandez-Cuenca, Pilar Perez-Romero
2011 Journal of Acquired Immune Deficiency Syndromes  
Optimizing treatment for patients with persistent lowlevel viremia is complicated because most genotyping tests are validated for viral loads .1000 copies per milliliter. In this study, genotypes of 92 treatment-experienced patients with persistent lowlevel viremia were determined using an in-house assay. Based on the resistance profiles obtained from genotyping and patient pharmacologic history, patients were either maintained on their antiviral regimen (n = 51) or received an optimized
more » ... (n = 41). In the group receiving optimized treatment, undetectable viral loads were achieved in 73.2% at 6 months and at 90.2% at 1 year, indicating that treatment guided by genotyping of patients with low-level viremia is effective in achieving viral suppression.
doi:10.1097/qai.0b013e3182364513 pmid:21963935 fatcat:md76ntmnwfcx5m644reefynxj4